22 Results for "

human pancreatic beta cells

" in MedChemExpress (MCE) Product Catalog:
Products (22)

22 Results for "human pancreatic beta cells" in MCE Product Catalog:

2
2 Cited Publications
Cat. No.: HY-P10102
CAS No.: 629628-53-1
Research Areas:  

Inflammation/Immunology Cancer

Kp7-6 is a Fas mimetic peptide and also a Fas/FasL antagonist. Kp7-6 specifically binds to Fas and FasL, disrupts receptor complexes, and blocks downstream apoptosis signaling pathways. Kp7-6 inhibits the phosphorylation of ERK1-2, induces the phosphorylation of IκBα, and activates NF-κB. Kp7-6 inhibits the activation of caspase-8, caspase-3 and JNK, and suppresses human amylin-induced β-cell apoptosis. Kp7-6 inhibits FasL-induced lymphoid cytotoxicity and apoptosis. Kp7-6 reduces local tumor FasL expression, increases CD8 +Fas + T cell infiltration, and decreases tumor volume in pancreatic neuroendocrine tumor models. Kp7-6 prevents concanavalin A-induced liver injury in mice. Kp7-6 is applicable to research related to type 2 diabetes, concanavalin A-induced hepatitis and pancreatic neuroendocrine tumors .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-P10086
CAS No.: 1289375-12-7
Synonyms: human TREM-1(213-221)
TREM-1 inhibitory peptide GF9 (Human TREM-1 (213-221)) is a TREM-1 inhibitor. TREM-1 inhibitory peptide GF9 blocks the TREM-1 signaling pathway via a ligand-independent mechanism, spontaneously inserts into the cell membrane to dissociate TREM-1 from DAP-12, and functions through the Signaling Chain Homooligomerization (SCHOOL) model. TREM-1 inhibitory peptide GF9 reduces the levels of TNFα, IL-1β, IL-6, and M-CSF. TREM-1 inhibitory peptide GF9 inhibits tumor growth, prolongs the survival of mice with pancreatic cancer models, ameliorates collagen-induced arthritis, and exerts protective effects on bone and cartilage simultaneously. TREM-1 inhibitory peptide GF9 can be used in research related to arthritis, pancreatic cancer, retinopathy, alcoholic liver disease, and liver cancer .
loading...
    loading...
1
1 Cited Publications
Cat. No.: HY-107535
CAS No.: 330981-72-1
Purity:  99.84%
Target:  

GPR119 TRP Channel

Research Areas:  

Metabolic Disease

AS1269574 is a potent, orally available GPR119 agonist, with an EC50 of 2.5 μM in HEK293 cells expressing human GPR119. AS1269574 activates TRPA1 cation channels to stimulate glucagon-like peptide-1 (GLP-1) secretion. AS1269574 specifically induces glucose-dependent insulin secretion from pancreatic β-cells only under high-glucose conditions. AS1269574 has the potential for the research of type 2 diabetes .
loading...
    loading...
Cat. No.: HY-120565
CAS No.: 1594041-84-5
WB403 is an orally active TGR5 activator with an EC50 of 5.5 μM against human TGR5. WB403 activates TGR5 to stimulate downstream signaling pathways, promote GLP-1 secretion, improve glucose tolerance in mice with type 2 diabetes, and reduce levels of fasting blood glucose, postprandial blood glucose and HbA1c. WB403 increases pancreatic β-cell mass and restores the distribution of α-cells and β-cells in islets. WB403 is applicable to the research of type 2 diabetes .
loading...
    loading...
Cat. No.: HY-P1654
CAS No.: 932699-03-1
Target:  

Integrin

Research Areas:  

Cancer

A20FMDV2 is a highly selective αvβ6 integrin inhibitor with human IC50 values of 3 nM and binds with at least 1000-fold selectivity over other RGD-binding integrins. A20FMDV2 binds to the integrin’s RGD-binding site, induces rapid integrin internalization, and delays post-internalization integrin recycling to the cell surface. A20FMDV2 can be used for the research of pancreatic cancer, breast cancer, colorectal cancer, ovarian cancer, oral squamous cell carcinoma .
loading...
    loading...
Cat. No.: HY-P3622
CAS No.: 215777-46-1
Target:  

GCGR

Research Areas:  

Metabolic Disease

(Ser8)-GLP-1 (7-36) amide, human is a glucagon-like peptide 1 amide derived from glucagonogen, a cleavage product of the GLP-1 (1-36) amide peptide. (Ser8)-GLP-1 (7-36) amide, human is an entero-insulinotropic hormone that causes glucose-dependent release of insulin from pancreatic β-cells and affects gastrointestinal motility and secretion .
loading...
    loading...
Cat. No.: HY-100534
CAS No.: 1136466-93-7
Purity:  ≥99.0%
IDE 2 is a cell-permeable inducer of definitive endoderm differentiation that induces the differentiation of mouse and human embryonic stem cells into definitive endoderm. IDE2 activates the TGF‑β/Nodal signaling pathway, induces Smad2 phosphorylation, and increases Sox17 and FoxA2 expression. Endoderm induced by IDE 2 integrates into the developing gut tube, expresses gut tube markers, and differentiates into pancreatic progenitor cells. IDE 2 can be used for research related to directed endoderm differentiation of embryonic stem cells .
loading...
    loading...
Cat. No.: HY-N2452
CAS No.: 956103-79-0
Cochinchinenin C is a GLP-1R agonist that binds to the extracellular domain of the receptor via hydrophobic interactions and hydrogen bonds, and promotes glucose-dependent insulin secretion from pancreatic β-cells. Cochinchinenin C also increases intracellular cAMP and ATP levels. At low concentrations, Cochinchinenin C binds to human serum albumin, alters its microenvironment, and induces dominant static fluorescence quenching. Cochinchinenin C shows almost no cytotoxicity to pancreatic β-cells, and exerts a synergistic effect with Loureirin A (HY-N1505) when binding to human serum albumin. Cochinchinenin C has been widely used in studies of type 2 diabetes, Helicobacter pylori infection, thrombotic diseases, and other conditions .
loading...
    loading...
Cat. No.: HY-P2501
CAS No.: 135702-23-7
Target:  

Amylin Receptor

Research Areas:  

Metabolic Disease

Amylin (8-37), human is a fragment of human Amylin. Amylin (8-37), human has direct vasodilator effects in the isolated mesenteric resistance artery of the rat. Human Amylin is a small hormone secreted by pancreatic β-cells that forms aggregates under insulin deficiency metabolic conditions, and it constitutes a pathological hallmark of type II diabetes mellitus .
loading...
    loading...
Cat. No.: HY-P990990
CAS No.: 2803875-75-2
Synonyms: YN011; YN012; YN015

Target:  

GLP Receptor

Efsubaglutide alfa is a long-acting humanised GLP-1 receptor agonist . Efsubaglutide alfa binds specifically to the GLP-1 receptor, enhancing glucose-dependent insulin secretion, suppressing glucagon release, and promoting β-cell proliferation and increased β-cell mass. Efsubaglutide alfa improves glucose tolerance, increases pancreatic insulin content, and enhances β-cell secretory responses in isolated human islets. Efsubaglutide alfa reduces liver steatosis, lowers NAFLD Activity Scores, improves perisinusoidal collagen features, reduces serum ALT and AST levels, improves fasting glucose and triglyceride levels, and reduces body weight, liver weight and liver-to-body weight ratio. Efsubaglutide alfa can be used for the research of type 2 diabetes. Efsubaglutide alfa can be used for the research of metabolic dysfunction-associated steatohepatitis .
loading...
    loading...
Cat. No.: HY-175420
CAS No.: 2696409-13-7
Research Areas:  

Metabolic Disease

K-757 is an orally active, gut-targeted GPR40 agonist with EC50 values of 2.1 nM, 5.6 nM, 4.2 nM and 166 nM in humans, mice, rats and dogs, respectively. K-757 activates nutrient receptors co-expressed on pancreatic β cells and intestinal enteroendocrine cells. K-757 mediates and induces the secretion of satiety hormones GLP-1 and PYY in multiple in vitro and in vivo models. When used in combination with GPR119 agonist K-833, K-757 acts as a potentiator to elevate circulating levels of satiety hormones. K-757 can be used in the research of type 2 diabetes, weight loss and other related metabolic disorders .
loading...
    loading...
Cat. No.: HY-111141
CAS No.: 916219-50-6
Research Areas:  

Metabolic Disease

AM-3189 is an orally active and selective GPR40 agonist with EC50 values in buffer solution and in 100% human serum of 33 nM and 10 μM respectively. AM-3189 shows no significant activity on GPR41 and GPR43, and no agonistic activity on PPAR-α, -δ, and -γ. AM-3189 enhances glucose-stimulated insulin secretion by activating GPR40 on pancreatic β cells. AM-3189 has extremely low penetration into the central nervous system and significantly reduces blood glucose levels in two humanized GPR40 mouse models. AM-3189 can be used for the study of type 2 diabetes .
loading...
    loading...
Cat. No.: HY-174559
Target:  

mRNA

Research Areas:  

Metabolic Disease

Human PAX4 mRNA encodes the human paired box 4 (PAX4) protein, a member of the paired box (PAX) family. PAX4 is involved in pancreatic islet development and mouse studies have demonstrated a role for this gene in differentiation of insulin-producing beta cells.
loading...
    loading...
Cat. No.: HY-169006
CAS No.: 2820245-53-0
Target:  

Apoptosis PKC

Research Areas:  

Cancer

Evo312 is a dose-dependent inhibitor of protein kinase CβⅠ (PKCβⅠ) (IC50 is 117.34 nM). Evo312 induces PANC-GR (acquired gemcitabine-resistant PC cells) cell cycle arrest and apoptosis by inhibiting PKCβ1 protein expression. Evo312 has antiproliferative effects in pancreatic cancer cells PANC-1 and PANC-GR cells with IC50 of 0.08 μM and 0.07 μM, and in human normal pancreatic ductal epithelial cells HPDE6-c7 with IC50 of 2.95 μM. Evo312 exhibits antitumor activity in a PANC-GR cell transplantation mouse model .
loading...
    loading...
Cat. No.: HY-123929
CAS No.: 1448427-02-8
Purity:  99.29%
Research Areas:  

Cancer

PAWI-2 is a p53-Activator and Wnt Inhibitor. PAWI-2 inhibits β3-KRAS signaling independent of KRAS. PAWI-2 selectively inhibits phosphorylation of TBK1. PAWI-2 activates apoptosis (activation of caspase-3/7), and induces PARP cleavage. PAWI-2 promotes optineurin translocation into the nucleus and causes G2/M arrest. PAWI-2 reverses cancer stemness and overcomes drug resistance in an integrin β3 KRAS-dependent human pancreatic cancer stem cells (hPCSCs). PAWI-2 inhibits growth of tumors from hPCSCs in orthopic xenograft mice model .
loading...
    loading...
Cat. No.: HY-174585
Target:  

mRNA

Research Areas:  

Metabolic Disease

Human MAFA mRNA encodes the human MAF bZIP transcription factor A (MAFA) protein, a transcription factor that regulates pancreatic beta cell-specific expression of the insulin gene.
loading...
    loading...
Cat. No.: HY-P12374
CAS No.: 121341-41-1
Target:  

Amylin Receptor

Research Areas:  

Metabolic Disease

hIAPP22-27 is a hexapeptide corresponding to residues 22-27 of human islet amyloid polypeptide (hIAPP) and is the key amyloid core sequence of hIAPP. hIAPP22-27 can self-assemble under neutral pH conditions to form β-sheet-containing amyloid fibrils and is cytotoxic to pancreatic β cells. hIAPP22-27 can be used in research related to type 2 diabetes .
loading...
    loading...
Cat. No.: HY-N20713
CAS No.: 118524-14-4
Licocoumarone is an active component derived from licorice. Licocoumarone has an IC50 of 12.56 μM and a Kd of 14.90 μM against human DYRK1A. Licocoumarone inhibits NF-κB activation by blocking IκBα degradation and p65 phosphorylation, interferes with MAPK activation via inhibiting phosphorylation, and downregulates the expression of iNOS. Licocoumarone inhibits LPS-induced expression of IL-1β, IL-6 and IL-10; it induces apoptosis of pancreatic cancer cells apoptosis and acts as a neuraminidase inhibitor (IC50 = 27.8 μM). Licocoumarone exhibits anti-inflammatory and antimicrobial activities, with antibacterial activity against Listeria and antifungal activity against Candida parapsilosis. Licocoumarone can be used in studies related to immune and inflammatory diseases, pancreatic cancer, and specific bacterial and fungal infections .
loading...
    loading...
Cat. No.: HY-D3174
CAS No.: 2688758-23-6
PiF is a fluorescent probe with high specificity for pancreatic β-cells (Ex/Em = 535 nm/565 nm), and its fluorescence signal increases significantly with elevated insulin concentrations in in vitro experiments. PiF enables visualization of rat and human islets transplanted via the portal vein in mouse livers with low liver background signals. The fluorine atom of PiF can be replaced by radioactive 18F to prepare a PET tracer. PiF can be used for research on type 1 diabetes .
loading...
    loading...
Cat. No.: HY-P992076
Anti-Candida auris β-1,3-glucans Antibody (2G8) is an antibody targeting Candida auris β-1,3-glucans, and also acts as an inhibitor of AChE and TGF-β receptor 2. Anti-Candida auris β-1,3-glucans Antibody (2G8) also targets fungal cell wall components, effectively inhibits fungal growth and interferes with capsule formation, thereby significantly reducing the fungal load in mouse tissues. Anti-Candida auris β-1,3-glucans Antibody (2G8) not only blocks TGF-β receptor binding to inhibit the Smad signaling pathway, reduces fibroblast activation and collagen deposition, but also induces epithelial differentiation of tumor cells and reduces pancreatic tumor metastasis. Anti-Candida auris β-1,3-glucans Antibody (2G8) specifically binds to the conserved N-linked glycoepitope on AChE to inhibit its activity without interfering with BChE, and can be used in studies of cryptococcosis and related tumor mechanisms .The isotype control is Human IgG1 kappa, Isotype Control (HY-P99001).
loading...
    loading...